Glycidol: Carcinogenic Potency Database

Glycidol (CAS 556-52-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
ezy lgi mgl nrv per ski sto thy	cli hmo mgl nrv orc sto thy	hag liv lun ski sto	hag mgl ski sub ute	4.28^m	34.7^m

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
vsc	vsc	56.1^m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: cli = clitoral gland. ezy = ear/Zymbal’s gland. hag = harderian gland. hmo = hematopoietic system. lgi = large intestine. liv = liver. lun = lung. mgl = mammary gland. nrv = nervous system. orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). per = peritoneal cavity. ski = skin. sto = stomach. sub = subcutaneous tissue. thy = thyroid gland. ute = uterus. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Glycidol: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



GLYCIDOL   556-52-5
3014 H f syg gav 14m24 2042                          0    17.9mg                                        Lijinsky;txih,8,267-271;1992
 spl hes eh     56.1mg   P<.05   +  19.3mg n.s.s.   0/12    4/20
 liv hcs e      244.mg   P<.4       39.8mg n.s.s.   0/12    1/20
 liv cho e      244.mg   P<.4       39.8mg n.s.s.   0/12    1/20
 lun adc e      no dre   P=1.       75.3mg n.s.s.   1/12    0/20
 tba tum e      71.8mg   P<.8       8.94mg n.s.s.   7/12   13/20
3015 H m syg gav 14m24 2042                          0    15.8mg
 for mal e      64.1mg   P<.08      19.4mg n.s.s.   0/12    3/19
 spl hes eh     99.1mg   P<.2    +  24.3mg n.s.s.   0/12    2/19
 liv hes e      204.mg   P<.4       33.2mg n.s.s.   0/12    1/19
 tba tum e      no dre   P=1.       14.0mg n.s.s.   7/12    9/19
3016 M f b6c gav 24m24 TR374 :                       0    17.7mg  35.4mg
 MXB MXB        15.3mg * P<.0005    10.2mg 26.6mg   5/50   21/50   37/50   hag:acn,adn; mgl:acn,adn,fba; ski:sqc,sqp; sub:fbs,srn;
                                                                                                                      ute:acn,can. C
 hag MXA        32.9mg * P<.0005 c  18.2mg 103.mg   4/50   11/50   17/50                                              hag:acn,adn.
 hag adn        36.0mg * P<.0005    19.4mg 128.mg   4/50   10/50   16/50                                                           S
 mgl acn        56.6mg * P<.0005    31.5mg 138.mg   1/50    5/50   15/50                                                           S
 mgl MXA        56.9mg * P<.0005 c  31.0mg 170.mg   2/50    6/50   15/50                                          mgl:acn,adn,fba.
 sub MXA        86.4mg * P<.0005 c  43.1mg 229.mg   0/50    3/50    9/50                                              sub:fbs,srn.
 sub srn        145.mg * P<.003     60.9mg 702.mg   0/50    1/50    6/50                                                           S
 ute MXA        127.mg * P<.02   c  51.3mg n.s.s.   0/50    3/50    3/50                                              ute:acn,can.
 MXA MXA        137.mg * P<.04      52.6mg n.s.s.   1/50    3/50    5/50      liv:hem,hes; ova:hem; pec:hes; sub:hes; ute:hem,hes. S
 ute acn        144.mg * P<.04      54.8mg n.s.s.   0/50    3/50    2/50                                                           S
 sub fbs        217.mg * P<.03      78.1mg n.s.s.   0/50    2/50    3/50                                                           S
 ski MXA        417.mg * P<.07   c  102.mg n.s.s.   0/50    0/50    2/50                                              ski:sqc,sqp.
 TBA MXB        27.5mg * P<.08      10.9mg n.s.s.  45/50   46/50   47/50
 liv MXB        76.0mg * P<.07      29.1mg n.s.s.   9/50    7/50   14/50                                          liv:hpa,hpc,nnd.
 lun MXB        96.7mg * P<.2       32.3mg n.s.s.   6/50   10/50    8/50                                              lun:a/a,a/c.
3017 M m b6c gav 24m24 TR374 :                       0    17.7mg  35.4mg
 hag MXA        41.7mg * P<.003  c  21.5mg 270.mg   8/50   12/50   22/50                                              hag:acn,adn.
 for sqp        97.5mg * P<.0005    48.3mg 274.mg   0/50    2/50    9/50                                                           S
 for MXA        100.mg * P<.003  c  47.7mg 533.mg   1/50    2/50   10/50                                              for:sqc,sqp.
 MXB MXB        29.2mg * P<.05      12.3mg n.s.s.  35/50   41/50   46/50  for:sqc,sqp; hag:acn,adn; liv:hpa,hpc; lun:a/a,a/c; ski:
                                                                                                                              sqp. C
 liv MXA        36.6mg * P<.04   c  15.8mg n.s.s.  24/50   31/50   35/50                                              liv:hpa,hpc.
 MXA MXA        38.8mg \ P<.03      15.4mg n.s.s.   5/50   12/50   (7/50)                                mul:mlh,mlm,mlp; thm:mlm. S
 liv hpa        41.2mg * P<.03      18.4mg n.s.s.  18/50   16/50   30/50                                                           S
 hag adn        60.4mg * P<.03      27.2mg n.s.s.   7/50   10/50   16/50                                                           S
 lun MXA        66.2mg * P<.07   c  26.2mg n.s.s.  13/50   11/50   21/50                                              lun:a/a,a/c.
 hag acn        148.mg * P<.02      61.5mg n.s.s.   1/50    2/50    7/50                                                           S
 ski sqp        253.mg * P<.02   c  86.5mg n.s.s.   0/50    0/50    4/50
 mul mlh        297.mg * P<.04      100.mg n.s.s.   0/50    1/50    3/50                                                           S
 epy srn        473.mg * P<.09   e  116.mg n.s.s.   0/50    0/50    2/50
 ubl tcc        761.mg * P<.3    e  186.mg n.s.s.   0/50    1/50    1/50
 TBA MXB        34.6mg * P<.2       12.6mg n.s.s.  42/50   47/50   49/50
 liv MXB        36.6mg * P<.04      15.8mg n.s.s.  24/50   31/50   35/50                                          liv:hpa,hpc,nnd.
 lun MXB        66.2mg * P<.07      26.2mg n.s.s.  13/50   11/50   21/50                                              lun:a/a,a/c.
3018 R f f34 gav 23m24 TR374 :                       0    26.5mg  53.6mg
 MXB MXB a      4.13mg / P<.0005    2.43mg 7.45mg  25/50   39/50   42/50  bra:gln; cli:acn,adn,can; for:sqc,sqp; mgl:acn,fba; mth:
                                                                                           sqc,sqp; mul:mnl; thy:fca,fcc; ton:sqp. C
 mgl MXA a      4.15mg / P<.0005 c  2.40mg 7.58mg  14/50   34/50   37/50                                              mgl:acn,fba.
 mgl fba a      4.55mg * P<.0005 c  2.52mg 8.70mg  14/50   32/50   29/50
 cli MXA a      12.5mg / P<.0005 c  5.27mg 36.5mg   5/50    9/50   12/50                                          cli:acn,adn,can.
 ute esp a      13.5mg * P<.0005    6.57mg 39.2mg  19/50   21/50   14/50                                                           S
 mul mnl a      14.0mg / P<.0005 c  7.12mg 32.9mg  13/50   14/50   20/50
 cli adn a      16.7mg * P<.0005    6.73mg 56.7mg   3/50    7/50    7/50                                                           S
 mgl acn a      23.0mg * P<.0005 c  11.9mg 46.8mg   1/50   11/50   16/50
 for MXA a      28.5mg / P<.0005 c  11.0mg 62.5mg   0/50    4/50   11/50                                              for:sqc,sqp.
 for sqp a      31.4mg / P<.0005    11.3mg 77.8mg   0/50    4/50    8/50                                                           S
 bra gln a      43.6mg * P<.0005 c  12.3mg 174.mg   0/50    4/50    4/50
 MXA MXA a      44.7mg * P<.0005 c  14.1mg 181.mg   1/50    3/50    7/50                                     mth:sqc,sqp; ton:sqp.
 MXA sqp a      46.7mg * P<.0005    14.4mg 212.mg   1/50    3/50    6/50                                         mth:sqp; ton:sqp. S
 ton sqp a      53.7mg * P<.0005    15.1mg 319.mg   1/50    3/50    5/50                                                           S
 cli MXA a      62.7mg * P<.008     14.0mg 2.21gm   2/50    2/50    5/50                                              cli:acn,can. S
 cli can a      64.1mg * P<.008     14.1mg 2.38gm   2/50    1/50    5/50                                                           S
 thy MXA a      68.2mg * P<.003  c  13.1mg 878.mg   0/50    1/50    3/50                                              thy:fca,fcc.
 pta adn a      30.6mg * P<.03      10.0mg n.s.s.  18/50   14/50    6/50                                                           S
 sub MXA a      71.1mg * P<.02      15.8mg n.s.s.   1/50    4/50    2/50                                              sub:fbs,fib. S
 adr MXA a      91.1mg / P<.04      17.7mg n.s.s.   2/50    0/50    3/50                                              adr:con,crn. S
 ute MXA a      130.mg / P<.02      20.1mg n.s.s.   1/50    0/50    4/50                                              ute:acn,adn. S
 for sqc a      317.mg * P<.02      94.6mg n.s.s.   0/50    0/50    3/50                                                           S
 thy fcc a      411.mg * P<.02      109.mg n.s.s.   0/50    0/50    3/50                                                           S
 stg fbs a      752.mg * P<.07   e  164.mg n.s.s.   0/50    0/50    2/50
 TBA MXB a      3.88mg / P<.0005    2.29mg 7.16mg  43/50   43/50   47/50
 liv MXB a      no dre   P=1.       n.s.s. n.s.s.   0/50    0/50    0/50                                          liv:hpa,hpc,nnd.
3019 R m f34 gav 93w98 TR374 :                       0    26.8mg  53.6mg
 tes ict a      1.49mg / P<.0005    .818mg 2.82mg  46/50   50/50   49/50                                                           S
 MXB MXB a      2.30mg / P<.0005    1.04mg 4.74mg   8/50   40/50   46/50  bra:gln; col:adc,adp; for:sqc,sqp; mgl:fba; ski:bct,sea,
                                                                                  sec; smi:mua; thy:fca,fcc; tnv:men,msm; zym:can. C
 mul mnl a      3.14mg / P<.0005    1.49mg 6.95mg  25/50   33/50   21/50                                                           S
 tnv MXA a      4.42mg / P<.0005 c  1.75mg 8.36mg   3/50   34/50   39/50                                              tnv:men,msm.
 tnv msm a      5.68mg / P<.0005    1.94mg 12.1mg   3/50   24/50   31/50                                                           S
 ski sqp a      7.00mg * P<.0005    1.31mg 80.1mg   0/50    3/50    3/50                                                           S
 bra gln a      7.32mg * P<.0005 c  1.31mg 74.5mg   0/50    5/50    6/50
 mgl fba a      7.97mg / P<.0005 c  2.65mg 27.8mg   3/50    8/50    7/50
 lun MXA a      10.7mg * P<.0005    2.61mg 70.1mg   2/50    5/50    4/50                                              lun:a/a,a/c. S
 pre adn a      10.8mg * P<.002     2.87mg 85.3mg   5/50    7/50    1/50                                                           S
 pre MXA a      11.2mg / P<.0005    3.43mg 68.2mg  10/50    7/50    5/50                                              pre:acn,adn. S
 pta MXA a      11.9mg * P<.005     2.94mg 205.mg   8/50    8/50    2/50                                              pta:adn,can. S
 pta adn a      13.1mg * P<.009     3.08mg 767.mg   8/50    7/50    2/50                                                           S
 thy MXA a      16.5mg / P<.0005 c  3.45mg 81.4mg   1/50    4/50    6/50                                              thy:fca,fcc.
 lun a/a a      17.0mg * P<.003     3.07mg 344.mg   1/50    3/50    2/50                                                           S
 thy fcc a      19.7mg / P<.0005    3.46mg 147.mg   1/50    2/50    5/50                                                           S
 ski ker a      21.6mg * P<.003     3.55mg 333.mg   1/50    4/50    1/50                                                           S
 sub MXA a      25.3mg / P<.0005    6.08mg 160.mg   4/50    5/50    5/50                                          sub:fbs,fib,nfm. S
 for MXA a      25.6mg / P<.0005 c  3.64mg 194.mg   1/50    2/50    6/50                                              for:sqc,sqp.
 tnv men a      25.8mg * P<.0005    10.8mg 61.5mg   0/50   10/50    8/50                                                           S
 ski MXA a      29.5mg / P<.0005 c  10.2mg 87.2mg   0/50    5/50    4/50                                          ski:bct,sea,sec.
 sub MXA a      30.0mg / P<.002     6.33mg 248.mg   4/50    4/50    5/50                                              sub:fbs,fib. S
 ski MXA a      30.6mg * P<.0005    10.3mg 98.1mg   0/50    5/50    3/50                                              ski:bct,sea. S
 ton MXA a      37.8mg * P<.006     3.94mg 1.42gm   1/50    1/50    4/50                                              ton:sqc,sqp. S
 ski bct a      38.8mg * P<.0005    11.1mg 176.mg   0/50    4/50    2/50                                                           S
 thy cca a      42.8mg / P<.005     7.41mg 651.mg   2/50    3/50    3/50                                                           S
 sub MXA a      42.9mg / P<.002     8.90mg 377.mg   2/50    3/50    4/50                                              sub:fib,nfm. S
 zym can a      49.8mg / P<.0005 c  14.7mg 235.mg   1/50    3/50    6/50
 sub fib a      55.9mg / P<.005     9.83mg 942.mg   2/50    2/50    4/50                                                           S
 for sqp a      101.mg / P<.0005    35.5mg 395.mg   0/50    1/50    5/50                                                           S
 MXA MXA a      244.mg * P<.004  c  89.0mg 1.88gm   0/50    1/50    4/50                                     col:adc,adp; smi:mua.
 MXA MXA a      72.3mg * P<.03      8.91mg n.s.s.   3/50    2/50    5/50                                 mth:sqc,sqp; ton:sqc,sqp. S
 TBA MXB a      1.66mg / P<.0005    .903mg 3.17mg  43/50   50/50   48/50
 liv MXB a      101.mg * P<.2       16.6mg n.s.s.   1/50    1/50    1/50                                          liv:hpa,hpc,nnd.

Mutagenicity in Salmonella: positive
SMILES Code for Glycidol: OCC1CO1
InChI Code for Glycidol: InChI=1/C3H6O2/c4-1-3-2-5-3/h3-4H,1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Glycidol:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007